Abstract: Copper(II) bromide mediated oxidation of acylated enol and use of the reaction in the synthesis of ?,?-unsaturated or ?-bromo ketones or aldehydes are disclosed. The method provides an efficient and practical process for manufacturing dehydrohedione (DHH) and many other versatile ?,?-unsaturated or ?-bromo ketones or aldehydes in large scales to avoid using precious metal compounds.

Abstract: The present invention relates to a process for the preparation of compounds or a mixture of compounds of the general formulae I.a or I.b wherein R1 is selected from C1-C12-alkyl, C3-C6-cycloalkyl, —C(?O)OR2, —PO(OR2a)2, aryl and hetaryl, R2, R2a are independently of each other selected from the group consisting of hydrogen, C1-C12-alkyl, C1-C12-alkenyl, where the last two radicals mentioned are unsubstituted, partly or completely halogenated or substituted by 1, 2, 3 or 4 radicals selected from the group consisting of C1-C6-alkoxy and CN, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C4-alkyl, aryl and aryl-C1-C4-alkyl, where the last four radicals mentioned are unsubstituted or substituted by 1, 2, 3 or 4 radicals selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, —CN, and halogen, which comprises dimerizing olefin compound of the general formula II, in the presence of at least one N-heterocyclic carbene catalyst.

Abstract: The present invention relates to a production process capable of selectively producing various kinds of carbonate compounds without restraint in high yields without using toxic compounds such as phosgene and crown ethers, without producing corrosive gases such as hydrogen chloride as a by-product, and without necessity of removing the chloroform as a by-product by distillation, and to a method for producing a carbonate compound, containing reacting compound (1) with a compound having an OH group in the presence of a metal salt and 0.2 to 4.0 mol of compound (2) per mol of the metal salt to obtain a carbonate compound, in which m is an integer of 1-10, Q is an alkylene group having 1 to 4 carbon atoms, etc, and R10 and R11 are alkyl groups having 1 to 5 carbon atoms, etc.

Abstract: A method of producing high purity dimethyl carbonate through the reaction of carbon dioxide and methanol is provided. In the ammonia-based method ammonia and carbon dioxide react to produce urea. The urea is mixed with methanol for further reaction to produce dimethyl carbonate. Ammonia released in the process is recycled as a reactant to produce more urea. It is then reacted with methanol to produce dimethyl carbonate. An integrated reactive distillation process using side reactors is used for facilitating catalytic reaction in the method for producing high purity dimethyl carbonate. The process is further enhanced by enclosing multiple side reactors into a pressure vessel and incorporating thermal heat pump for recovery and reuse of latent heat within the process.

Abstract: Polyol esters of metathesized fatty acids are generally disclosed herein. Methods of using such compounds, for example, as cleaning agents, solvents, and coalescents for paints and coatings, are also disclosed.

Abstract: The present invention includes methods for producing and purifying esters of polyunsaturated fatty acids that include reacting a composition having triglycerides with polyunsaturated fatty acid residues in the presence of an alcohol and a base to produce an ester of a polyunsaturated fatty acid from the triglycerides. The composition can be a polyunsaturated fatty acid-containing composition that has not been conventionally processed. The reacted composition can be further processed by distillation.

Abstract: The present invention relates to novel compounds, e.g. for use as a medicament. In particular, the present invention relates to novel prodrugs of monomethyl fumarate (MMF) suitable as a medicament, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases, inflammatory diseases, for example multiple sclerosis and psoriasis.

Abstract: The invention provides compounds and methods, for example, to carry out organocatalytic Michael additions of aldehydes to cyclically constrained nitroethylene compounds catalyzed by a proline derivative to provide cyclically constrained ?-substituted-?-nitro-aldehydes. The reaction can be rendered enantioselective when a chiral pyrrolidine catalyst is used, allowing for Michael adducts in nearly optically pure form (e.g., 96 to >99% e.e.). The Michael adducts can bear a single substituent or dual substituents adjacent to the carbonyl. The Michael adducts can be efficiently converted to cyclically constrained protected ?-amino acid residues, which are essential for systematic conformational studies of ?-peptide foldamers. New methods are also provided to prepare other ?-amino acids and peptides. These new building blocks can be used to prepare foldamers, such as ?/?-peptide foldamers, that adopt specific helical conformations in solution and in the solid state.

Abstract: The present invention relates to an amine of the formula (I) which is an adduct of 1,2-propylenediamine with an aryl monoglycidyl ether, to the use thereof as part of a hardener for epoxy resins, and to epoxy resin compositions obtained therewith. The amine of the formula (I) is preparable in a simple process in high purity, is of very low viscosity and is especially suitable for the curing of epoxy resins. It allows low-emission epoxy resin compositions which have good workability and which cure even under cold and damp conditions, quickly and without blushing effects, to form very hard products of high surface quality that display virtually no yellowing on exposure to light.

Abstract: Esteramine compositions and their derivatives are disclosed. The esteramines comprise a reaction product of a metathesis-derived C10-C17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives with a tertiary alkanolamine. Derivatives made by quaternizing, sulfonating, alkoxylating, sulfating, and/or sulfitating the esteramines are also disclosed. In one aspect, the ester derivative of the C10-C17 monounsaturated acid or octadecene-1,18-dioic acid is a lower alkyl ester. In other aspects, the ester derivative is a modified triglyceride made by self-metathesis of a natural oil or an unsaturated triglyceride made by cross-metathesis of a natural oil with an olefin. The esteramines and derivatives are valuable for a wide variety of end uses, including cleaners, fabric treatment, hair conditioning, personal care (liquid cleansing products, conditioning bars, oral care products), antimicrobial compositions, agricultural uses, and oil field applications.

Abstract: The invention relates to a fatty amide, which is based on: a) a diamine selected from aromatic or cycloaliphatic or linear C2 to C10 aliphatic diamines, b) a C3 to C12 lactam or amino acid, c) optionally, a second primary diamine different from said diamine a), d) a hydroxylated fatty monoacid, e) optionally, a nonhydroxylated monoacid chosen from linear C6 to C12 aliphatic acids, with a mole ratio b/(a+c) of 0.25 to 3/1. The invention also covers a process for the preparation of said amide and its use as organogelator or rheology additive in an organic solvent medium, in particular in coating, glue or adhesive, mastic, sealant or stripping agent compositions or molding or cosmetic compositions.

Abstract: This invention relates to compounds of Formula (I) wherein Cy1, L1, Y, R1, L2, and Ar2 are defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions.

Abstract: The present invention relates to a novel pseudoceramide derivative, a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutical or cosmetic composition containing the same as an active ingredient. The novel pseudoceramide derivative of the present invention is expected to be very useful for treating or preventing skin diseases by activating cannabinoid receptors. In addition, the novel pseudoceramide derivative, the pharmaceutically acceptable salt thereof or the solvate thereof, of the present invention, has a simple synthesis process compared with a known cannabinoid receptor antagonist so as to reduce processing time and curtail material costs, and thus is economical, and has advantages such as easy emulsification during the formulation of cosmetic products or medical supplies.

Abstract: The present invention is directed to a new class of lipids, more specifically ether-lipids having a polar headgroup, as well as vesicles comprising these lipids, methods of their preparation as well as their uses in medical applications, wherein the ether-lipids are represented by general formula I

Abstract: Provided are compounds and compositions thereof that are useful as antioxidants in personal care formulations. The compounds are of the Formula I: wherein R1, R2, R3, R4, and R5 are independently H, —OH, C1-C6 alkoxy, —COOH, —COO?M+ or —O31 M+, where M+ is a sodium, potassium, or ammonium ion, wherein at least two of R1, R2, R3, R4, or R5 are —OH, and R6, R7, R8, R9, and R10, are independently H, —OH, C1-C6 alkoxy, —COOH, —COO?M+ or —O?M+ where M+ is a sodium, potassium, or ammonium ion, or a substituent of Formula II: wherein R11, R12, R13, R14,and R15are independently H, —OH, C1-C6 alkoxy, —COOH, —COO?M+ or —O?M+, where M+ is a sodium, potassium, or ammonium ion, provided that one of R6, R7, R8, R9, and R10 is a substituent of Formula II.

Abstract: This invention provides novel compounds comprising the following anti-inflammatory pharmacore: wherein X, R1 and R2 are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.

Abstract: The invention relates to a method for preparing isocyanates by the phosgenation of the corresponding amines in which problems resulting from the formation of deposits in apparatuses of the reaction segment during activation (starting) and deactivation (termination) of the method can be prevented by processing measures, in particular ensuring that there is a surplus of phosgene relative to the phosgenating amine during the critical starting and termination steps of the method.

Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as HMC compounds) that are useful, for example, in the treatment of disorders (e.g.

Abstract: The invention provides compounds of the formula: and salts thereof that are useful as intermediates for preparing corresponding compounds of formula I: that are useful for treating conditions associated with Aurora B kinase activity (e.g. cancer).

Abstract: Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.

Abstract: The subject invention provides pridopidine L-tartrate, compositions and a process for manufacture thereof.

Abstract: Compositions and methods for treatment and prevention of disorders and conditions characterized by reduced TGF-B signaling are described. In particular, the compositions and methods are useful for reducing or eliminating the pathologies associated with Alzheimer's disease. The compositions include urea derivatives containing a piperidine, piperidinium, or a piperidin-4-yl methyl; cycloalkyl, aryl, and fluorobenzyl moieties.

Abstract: A paroxetine intermediate, a method for preparing the same, and uses thereof are provided. Specifically, the method includes: reacting a compound of formula I below with a compound of formula II in the presence of an organic base under the catalysis of a complex formed from a chiral amine oxide L and a rare-earth metal compound Ln(OTf)3 to prepare a compound of formula III below: wherein R1 is alkyl, phenyl or benzyl; R2, R3, R4 are each independently C1-C6 alkyl or C6-C10 aryl; the chiral amine oxide L has the following structure: wherein n=1, 2; and R=Ph—, 2,6—Me2C6H3—, 2,6—Et2C6H3—, 2,6-iPr2C6H3—, Ph2CH—.

Abstract: The present specification discloses honeybee repellents exhibiting repellent properties similar to 2-heptanone, compositions comprising such repellents, uses to repel a honeybee from a mammal, location, plant, structure treated of such repellents, and methods of treating a mammal, location, plant, structure by applying such repellents.

Abstract: Provided is a novel compound which has an excellent A? aggregation inhibitory effect and is useful as a pharmaceutical. An amide compound represented by the formula (1) or a salt thereof, wherein Z represents CH or N; A and B are the same or different and each represents —CH2—, —O—, —S—, or —NH—; R1 and R2 are the same or different and each represents a branched alkyl group, a branched alkenyl group, an optionally substituted aromatic hydrocarbon group, an optionally substituted aralkyl group, an optionally substituted cycloalkyl group, or an optionally substituted aromatic heterocyclic group; and R3 represents a branched alkyl group, a branched alkenyl group, an optionally substituted cycloalkyl group, or an optionally substituted aralkyl group.

Abstract: The present invention provides a method for manufacturing an optically active compound of formula (2), which contains bringing hydrogen into contact with a compound of formula (1) in the presence of a transition metal catalyst having an optically active ligand. In the formula, R1 represents a hydrogen atom or an acetyl group, R2, R3, R4, and R5 each independently represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, a hydroxy group, a nitro group, an amino group, or an acyl group, R6 represents an alkyl group, R7 and R8 each independently represents a hydrogen atom or an alkyl group, and a carbon atom marked with an asterisk (*) represents an asymmetric carbon atom.

Abstract: Compounds for inhibiting Type 4 Prepilin Peptidases are provided as are methods of using the compounds as anti-bacterial agents.

Abstract: The invention provides isofogamine analogs of structural formula (I) below that modulate and stabilize glucocerebrosidases and enhance their enzymatic activity in vivo. Such compounds, prodrugs and compositions thereof are useful in treating synucleinopathy, lysosomal storage disease and relevant neurodegenerative disease.

Abstract: Embodiments of bridged tetrahydroisoquinolines and methods for their use in selectively inhibiting nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 2 are disclosed. The disclosed compounds have a structure according to general formula I or a pharmaceutically acceptable salt thereof: wherein “” represents a single or double bond, R1 is hydrogen, halogen, lower aliphatic, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; Ra is hydrogen, —CH2R2, R3, or —SO2R4; R2 is lower aliphatic, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R3 is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R4 is lower aliphatic, or substituted or unsubstituted aryl; and R5 is hydrogen, halogen, or lower aliphatic.

Abstract: The present application provides processes for making pesticidal compounds and compounds useful both as pesticides and in the making of pesticidal compounds.

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.

Abstract: The invention relates to pyrimidine derivatives according to formula (I), and to organic electroluminescent devices comprising said pyrimidine derivatives as electron transport material.

Abstract: Provided are pharmaceutical compositions and dosage forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof. Also provided are methods of treating, managing, or preventing various disorders, such as diseases or disorders treatable or preventable by inhibition of a JNK pathway in mammals using such pharmaceutical compositions or dosage forms. Further provided are salts of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide and methods of preparation of such salts.

Abstract: The invention relates to antibacterial compounds of formula I wherein R1 is H or halogen; R2 is the group M; R3 is H or halogen; M is MA or MB wherein A is a bond or C?C; R1A is H or halogen; R2A is H, alkoxy or halogen; R3A is H, alkoxy, hydroxyalkoxy, hydroxyalkyl, 1,2-dihydroxyethyl, dialkylamino, 1-hydroxymethyl-cycloprop-1-yl, 1-((dimethylglycyl)oxy)methyl-cycloprop-1-yl, 3-hydroxyoxetan-3-yl, morpholin-4-ylalkyl or morpholin-4-ylalkoxy; and R1B is a group as defined in claim 1; and salts thereof.

Abstract: The present invention relates to a family of S-substituted quinazoline derivatives that inhibitors of the enzyme phosphodiesterase 7 (PDE7), useful for the treatment or prevention of diseases mediated by said enzyme, especially inflammatory, neurodegenerative, neurological, psychiatric and/or autoimmune diseases.

Abstract: Provided is a method for the synthesis of N-protected bis-3,6-[4-aminobutyl]-2,5-diketopiperazine including the step of heating a solution of ?-amino protected lysine in the presence of a catalyst selected from the group consisting of sulfuric acid, phosphoric acid, and phosphorus pentoxide.

Abstract: By either forming a triaryl acid halide or a triaryl mixed anhydride and subsequently treating with aqueous sodium azide, triaryl acyl azides are prepared in high yield using inexpensive reagents in a process in which by-products are easily removed from the triaryl acyl azide.

Abstract: The present invention relates to a novel process for preparing dihydroisoxazole derivatives.

Abstract: Partially fluorinated ketones are provided that include a terminal alkyl group having from 1 to 6 carbon atoms bonded to a carbonyl group and a hydrofluoroether moiety having from 2 to 4 carbon atoms that contains at least one hydrogen substituent. The hydrofluoroether moiety is bonded to the carbonyl group with a carbon-carbon bond. The ether oxygen is bonded to a carbon atom that is at least two carbon atoms removed from the carbonyl group. Additionally, a fluorinated alkyl group having from 1 to 10 carbon atoms is bonded to the ether oxygen of the hydrofluoroether moiety. These partially fluorinated ketones can be used in a wide variety of electronics applications.

Abstract: Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme, as well as methods of synthesizing these novel compounds. The compounds may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases.

Abstract: The present invention relates to a method for prevention of premature polymerization during the preparation, purification, transportation and storage of a polymerizable compound with at least one conjugated unsaturated group in the presence of an azine dye-based compound as inhibitor. Further the present invention relates to methods of preparing such inhibitors as well as to the inhibitors itself, as well as to methods of improving solubility and stability of dissolved inhibitors.

Abstract: The present invention provides compounds and methods for modulation of the quorum sensing of bacteria. In an embodiment, the compounds of the present invention are able to act as replacements for naturally occurring bacterial quorum sensing ligands in a ligand-protein binding system; that is, they imitate the effect of natural ligands and produce an agonistic effect. In another embodiment, the compounds of the present invention are able to act in a manner which disturbs or inhibits the naturally occurring ligand-protein binding system in quorum sensing bacteria; that is, they produce an antagonistic effect. The compounds of the present invention comprise N-acylated-homoserine lactones (AHLs) comprised of a wide range of acyl groups.

Abstract: Provided herein are novel, commercially viable and industrially advantageous processes for the preparation of benzofuran-2-carboxamide derivatives and their intermediates, or a pharmaceutically acceptable salt thereof, in high yield and purity. Provided particularly herein are novel, commercially viable and industrially advantageous processes for the preparation of vilazodone or a pharmaceutically acceptable salt thereof in high yield and purity. Provided also herein is an improved and commercially viable process for the preparation of 3-(4-hydroxybutyl)-1H-indole-5-carbonitrile, in high yield and purity, using novel intermediate compound 3-(4-hydroxybutyryl)-1H-indole-5-carbonitrile.

Abstract: Disclosed herein is a compound of the formula Therapeutic methods, compositions, and medicaments, related thereto are also disclosed.

Abstract: Compounds comprising a fused tricylic core that modulate HIF-2? activity, pharmaceutical compositions containing these chemical entities, and methods of using these chemical entities for treating diseases associated with HIF-2? activity are described herein.

Abstract: Provided herein are isoindoline compounds, pharmaceutical compositions comprising one or more of such compounds, and methods of their use for treating, preventing, or managing various diseases.

Abstract: The present invention relates to certain intermediates useful in the preparation of certain benzoimidazol-2-yl pyrimidines and processes for preparing them.

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.

Abstract: The invention relates to a CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers; a pharmaceutical formulation, pharmaceutical composition and kit comprising said CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers, and use of said CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers. For example, the compounds of the invention are useful for reducing or inhibiting the activity of CDK4/6 kinase in a cell, and/or treating and/or preventing a cancer-related disease mediated by CDK4/6 kinase.

Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, m and n are as described herein, compositions including the compounds and methods of using the compounds.